|
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy Clinical research trials and Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy. Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy clinical trial. Human subjects often receive the most effective healthcare possible for their Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
For Condition: adenocarcinoma of the prostate,recurrent prostate cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Cancer and Leukemia Group B
Synopsis: RATIONALE: Gene mutations may make prostate cancer cells unable to attach to androgens. This may permit the growth of prostate cancer. Gene testing may improve the identification of patients with advanced prostate cancer. PURPOSE: Clinical trial to study the androgen receptor gene in patients with prostate cancer that is not responsive to hormone therapy.
Details: OBJECTIVES: I. Test the feasibility of obtaining bone marrow specimens in a cooperative group setting. II. Determine the frequency of bone marrow invasion by prostate cancer cells in patients with hormone refractory prostate cancer. III. Evaluate the frequency of androgen receptor (AR) mutations in bone marrow samples in this patient population. IV. Evaluate the association between AR mutations and clinical outcomes, including survival, and response to therapy, such as antiandrogen withdrawal. V. Evaluate the impact of prior pelvic radiotherapy on the ability to obtain informative tissue. PROTOCOL OUTLINE: Blood and a bone marrow biopsy are collected from each patient before the patient begins treatment on CLB-9480 or CLB-9583. The specimens are analyzed for androgen receptor mutations. Patients do not receive results of the genetic testing and the results do not influence the type or duration of treatment. PROJECTED ACCRUAL: A total of 243 patients will be accrued for this study.
Eligibility:
Study Type: Observational, Cross-Sectional
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven adenocarcinoma of the prostate that is refractory to hormone therapy - Eligible for any prostate cancer chemotherapy protocol, but have not started treatment - Patients who are eligible for anticancer therapy on Protocol CLB-9480, CLB-9583, CLB-9680, or CLB-9780 are also eligible for this study if they have not started treatment on those protocols --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: Any age - Performance status: CALGB 0-2 - Life expectancy: See Disease Characteristics - Hematopoietic: See Disease Characteristics - Hepatic: See Disease Characteristics - Renal: See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MaryTaplin, Study Chair, Cancer and Leukemia Group B
State University of New York - Upstate Medical University
Syracuse, New York, 13210
United States
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
Winston Salem, North Carolina, 27157-1082
United States
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455
United States
University of Illinois at Chicago Health Sciences Center
Chicago, Illinois, 60612
United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198-3330
United States
Veterans Affairs Medical Center - Buffalo
Buffalo, New York, 14215
United States
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
MBCCOP - Massey Cancer Center
Richmond, Virginia, 23298-0037
United States
New York Presbyterian Hospital - Cornell Campus
New York City, New York, 10021
United States
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
United States
CCOP - North Shore University Hospital
Manhasset, New York, 11030
United States
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
Syracuse, New York, 13210
United States
St. Barnabas Medical Center
Livingston, New Jersey, 07039
United States
Mount Sinai Medical Center, NY
New York City, New York, 10029
United States
Veterans Affairs Medical Center - San Francisco
San Francisco, California, 94121
United States
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210
United States
Veterans Affairs Medical Center - White River Junction
White River Junction, Vermont, 05009
United States
Veterans Affairs Medical Center - Durham
Durham, North Carolina, 27705
United States
University of Tennessee, Memphis Cancer Center
Memphis, Tennessee, 38163
United States
Vincent T. Lombardi Cancer Research Center, Georgetown University
Washington D.C., District of Columbia, 20007
United States
Veterans Affairs Medical Center - Columbia (Truman Memorial)
Columbia, Missouri, 65201
United States
Rhode Island Hospital
Providence, Rhode Island, 02903
United States
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts, 01655
United States
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, 21201
United States
University of California San Diego Cancer Center
La Jolla, California, 92093-0658
United States
Veterans Affairs Medical Center - Memphis
Memphis, Tennessee, 38104
United States
CCOP - Christiana Care Health Services
Wilmington, Delaware, 19899
United States
Barnes-Jewish Hospital
St. Louis, Missouri, 63110
United States
Veterans Affairs Medical Center - Birmingham
Birmingham, Alabama, 35233
United States
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94115-0128
United States
Veterans Affairs Medical Center - Richmond
Richmond, Virginia, 23249
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Veterans Affairs Medical Center - Minneapolis
Minneapolis, Minnesota, 55417
United States
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5000
United States
CCOP - Southeast Cancer Control Consortium
Winston Salem, North Carolina, 27104-4241
United States
Veterans Affairs Medical Center - Chicago (Westside Hospital)
Chicago, Illinois, 60612
United States
Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756
United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
United States
Veterans Affairs Medical Center - Syracuse
Syracuse, New York, 13210
United States
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
United States
CCOP - Mount Sinai Medical Center
Miami, Florida, 33140
United States
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637
United States
St. Joseph's Hospital and Medical Center
Paterson, New Jersey, 07503
United States
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, 65203
United States
North Shore University Hospital
Manhasset, New York, 11030
United States
Veterans Affairs Medical Center - Togus
Togus, Maine, 04330
United States
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Additional Information:
Study ID Numbers: CDR0000065329; CLB-9663
Study Start Date: January 1997
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002924
Other Adenocarcinoma Of The Prostate Studies:
1. MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
2. Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
3. Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
4. Epoetin alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
5. Morphine Plus Marijuana in Treating Pain Caused by Bone Metastases in Patients With Breast or Prostate Cancer
Related Studies:
Other adenocarcinoma of the prostate Clinical Trials
Other New York Clinical Trials
Other Syracuse Clinical Trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
|
|
|
|
|
|
|
|